Clinical relevance of EGFR- and KRAS-status in colorectal cancer patients treated with monoclonal antibodies directed against the EGFR
- 31 May 2009
- journal article
- review article
- Published by Elsevier BV in Cancer Treatment Reviews
- Vol. 35 (3), 262-271
- https://doi.org/10.1016/j.ctrv.2008.11.005
Abstract
No abstract availableThis publication has 84 references indexed in Scilit:
- Molecular Mechanisms of Epidermal Growth Factor Receptor (EGFR) Activation and Response to Gefitinib and Other EGFR-Targeting DrugsClinical Cancer Research, 2006
- Multicenter Phase II and Translational Study of Cetuximab in Metastatic Colorectal Carcinoma Refractory to Irinotecan, Oxaliplatin, and FluoropyrimidinesJournal of Clinical Oncology, 2006
- Epidermal growth factor receptor expression and gene amplification in colorectal carcinoma: an immunohistochemical and chromogenic in situ hybridization studyLaboratory Investigation, 2005
- Molecular Determinants of Cetuximab EfficacyJournal of Clinical Oncology, 2005
- Cetuximab Shows Activity in Colorectal Cancer Patients With Tumors That Do Not Express the Epidermal Growth Factor Receptor by ImmunohistochemistryJournal of Clinical Oncology, 2005
- Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal CancerThe New England Journal of Medicine, 2004
- Phase II Trial of Cetuximab in Patients With Refractory Colorectal Cancer That Expresses the Epidermal Growth Factor ReceptorJournal of Clinical Oncology, 2004
- Epidermal growth factor receptor immunohistochemical reactivity in patients with American Joint Committee on Cancer Stage IV colon adenocarcinomaCancer, 2001
- Transforming Growth Factor-β1 Promotes Invasiveness after Cellular Transformation with Activated Ras in Intestinal Epithelial CellsExperimental Cell Research, 2001
- Regulation of signal transduction and signal diversity by receptor oligomerizationTrends in Biochemical Sciences, 1994